Implications of isoniazid resistance in Mycobacterium bovis Bacillus Calmette-Guérin used for immunotherapy in bladder cancer

13Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We report a case of sepsis from Mycobacterium bovis Bacillus Calmette-Guérin (BCG) with low-level isoniazid resistance following intravesical treatment for bladder cancer. Isoniazid resistance in BCG has therapeutic implications when it causes infections after intravesical instillation. For these circumstances, we propose some modifications to existing treatment guidelines for BCG infection. © The Author 2011.

Cite

CITATION STYLE

APA

Watts, M. R., Taylor, P. C., Sintchenko, V., Whelan, C. M., Farnsworth, R. H., Jones, P., … Goldberg, H. (2011). Implications of isoniazid resistance in Mycobacterium bovis Bacillus Calmette-Guérin used for immunotherapy in bladder cancer. Clinical Infectious Diseases, 52(1), 86–88. https://doi.org/10.1093/cid/ciq002

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free